.jpg)
Eyconis
Founded 2023 · $150.0M raised
- Founded
- 2023
- Website
- eyconis.com
- Total Funding
- $150.0M
- Last Round
- $150.0M Venture RoundJan 2024
- Rounds
- 1
About
Eyconis is a clinical-stage biotechnology company developing long-acting ophthalmic therapeutics for serious eye diseases, including wet age-related macular degeneration. Its programs seek to transform the ophthalmology treatment paradigm through sustained treatment approaches for patients with debilitating retinal conditions. The company was formed as a spinout of Ascendis Pharma and is advancing EYC-0305 in a first-in-human clinical trial.
Summary
Eyconis is a Biotech company, founded in 2023. It has raised $150.0M in total across 1 round, most recently a $150.0M Venture Round round in Jan 2024. Investors include Frazier Life Sciences, RA Capital Management and venBIO Partners.
Tech & App Stack
2 technologies & apps tracked
Every product and vendor across these categories, with where each signal came from.
Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.
Funding History
Jan 2024
Investors
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Simtra provides pharmaceutical and biotech clients development and manufacturing services for ste...
IVI-RMA provides fertility treatments and patient-centered reproductive care, combining research,...
inVentiv Health merged with INC Research to form Syneos Health, integrating clinical and commerci...
Altos Labs combines academic science and industry development to create medicines that restore ce...
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/eyconis"><img src="https://indexed.vc/api/badge/company/eyconis" alt="Eyconis on Indexed.vc" width="260" height="76" /></a>